Search

Your search keyword '"Van Den Neste, Eric"' showing total 712 results
Start Over Author "Van Den Neste, Eric"
712 results on '"Van Den Neste, Eric"'

1. R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma (HOVON/SAKK): final results of a multicentre, phase 3, open-label, randomised trial

Author

Chamuleau, Martine E D, Stenner, Frank, Chitu, Dana A, Novak, Urban, Minnema, Monique C, Geerts, Paul, Stevens, Wendy B C, Zenz, Thorsten, van Imhoff, Gustaaf W, Wu, Ka Lung, Demandt, Astrid M P, Kersten, Marie Jose, Terpstra, Wim E, Tick, Lidwine W, Deeren, Dries, Van Den Neste, Eric, Gregor, Michael, Veelken, Hendrik, Böhmer, Lara H, Caspar, Clemens B, Mutsaers, Pim, Refos, Jeannine M, Sewsaran, Robby, Fu, Liping, Seefat, Rianne L, Uyl-de Groot, Carin A, Dirnhofer, Stefan, Van Den Brand, Michiel, de Jong, Daphne, Nijland, Marcel, and Lugtenburg, Pieternella

Published
2023
Full Text
View/download PDF

2. Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA study

Author

Bachy, Emmanuel, Houot, Roch, Feugier, Pierre, Bouabdallah, Krimo, Bouabdallah, Reda, Virelizier, Emmanuelle Nicolas, Maerevoet, Marie, Fruchart, Christophe, Snauwaert, Sylvia, Le Gouill, Steven, Marolleau, Jean-Pierre, Molina, Lysiane, Moluçon-Chabrot, Cécile, Thieblemont, Catherine, Tilly, Hervé, Bijou, Fontanet, Haioun, Corinne, Van den Neste, Eric, Fabiani, Bettina, Meignan, Michel, Cartron, Guillaume, Salles, Gilles, Casasnovas, Olivier, and Morschhauser, Franck

Published
2022
Full Text
View/download PDF

3. Intravascular large cell B lymphoma presenting as central nervous system pseudo-vasculitis: A rare diagnostic challenge.

Author

Vandermeersch, Denis, Mahsouli, Amin, Willemart, Mathilde, Scoppettuolo, Pasquale, Van de Wyngaert, Caroline, Van den Neste, Eric, Camboni, Alessandra, Lawson, Morel, Onofrj, Valeria, and Pothen, Lucie

Abstract

Intravascular large B cell lymphoma (IVLBCL) is a very rare subtype of aggressive non-Hodgkin B cell lymphoma characterized by intravascular proliferation of clonal B lymphocytes, classically associated with pulmonary and cutaneous disease and, less frequently, with central nervous system (CNS) involvement. Brain imaging findings are usually non-specific, with evidence of multiple vascular occlusions and stroke as non-specific multifocal abnormalities. We present an exceptionally rare case of IVLBCL in a patient with unexplained inflammatory syndrome with B symptoms and rapidly progressive neurological impairment, with multifocal hemorrhagic and tumefactive brain lesions seen on MRI. We suggest that in this clinical setting, the presence of tumefactive and hemorrhagic lesions should raise suspicion for IVLBCL and lead to the decision to perform a biopsy, which, nonetheless, remains the diagnostic gold standard. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

4. Recommendations for The Management of Patients with Hairy-Cell Leukemia and Hairy-Cell Leukemia-Like Disorders: A Work by French-Speaking Experts and French Innovative Leukemia Organization (FILO) Group

Author

Paillassa, Jérôme, primary, Maitre, Elsa, additional, Belarbi Boudjerra, Nadia, additional, Madani, Abdallah, additional, Benlakhal, Raihane, additional, Matthes, Thomas, additional, Van Den Neste, Eric, additional, Cailly, Laura, additional, Inchiappa, Luca, additional, Bekadja, Mohammed Amine, additional, Tomowiak, Cécile, additional, and Troussard, Xavier, additional

Published
2024
Full Text
View/download PDF

5. Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma

Author

Neelapu, Sattva S., Locke, Frederick L., Bartlett, Nancy L., Lekakis, Lazaros J., Reagan, Patrick M., Miklos, David B., Jacobson, Caron A., Braunschweig, Ira, Oluwole, Olalekan O., Siddiqi, Tanya, Lin, Yi, Crump, Michael, Kuruvilla, John, Van Den Neste, Eric, Farooq, Umar, Navale, Lynn, DePuy, Venita, Kim, Jenny J., and Gisselbrecht, Christian

Published
2021
Full Text
View/download PDF

7. Oxaliplatin before autologous transplantation in combination with high-dose cytarabine and rituximab provides longer disease control than cisplatin or carboplatin in patients with mantle-cell lymphoma: results from the LyMA prospective trial

Author

Tessoulin, Benoit, Chiron, David, Thieblemont, Catherine, Oberic, Lucie, Bouadballah, Kamal, Gyan, Emmanuel, Damaj, Gandhi, Ribrag, Vincent, Gressin, Rémy, Feugier, Pierre, Casasnovas, Olivier, Zerazhi, Hacène, Lemonnier, François, Maisonneuve, Hervé, Joubert, Clementine, Van Den Neste, Eric, Lamy, Thierry, Tilly, Hervé, Moreau, Anne, Hermine, Olivier, and Le Gouill, Steven

Published
2021
Full Text
View/download PDF

8. Prognostic impact of genetic abnormalities in 536 first‐line chronic lymphocytic leukaemia patients without 17p deletion treated with chemoimmunotherapy in two prospective trials: Focus on IGHV‐mutated subgroups (a FILO study).

Author

Nguyen‐Khac, Florence, Baron, Marine, Guièze, Romain, Feugier, Pierre, Fayault, Alexandra, Raynaud, Sophie, Troussard, Xavier, Droin, Nathalie, Damm, Frederik, Smagghe, Luce, Susin, Santos, Leblond, Véronique, Dartigeas, Caroline, Van den Neste, Eric, Leprêtre, Stéphane, Bernard, Olivier A., and Roos‐Weil, Damien

Subjects
LYMPHOCYTIC leukemia, PROGNOSIS, CHRONIC lymphocytic leukemia, GENETIC mutation, BRUTON tyrosine kinase
Abstract

Summary: The potential prognostic influence of genetic aberrations on chronic lymphocytic leukaemia (CLL) can vary based on various factors, such as the immunoglobulin heavy variable (IGHV) status. We conducted an integrative analysis on genetic abnormalities identified through cytogenetics and targeted next‐generation sequencing in 536 CLL patients receiving first‐line chemo(immuno)therapies (CIT) as part of two prospective trials. We evaluated the prognostic implications of the main abnormalities, with specific attention to their relative impact according to IGHV status. In the entire cohort, unmutated (UM)‐IGHV, complex karyotype, del(11q) and ATM mutations correlated significantly with shorter progression‐free survival (PFS). Focusing on the subset of mutated IGHV (M‐IGHV) patients, univariate analysis showed that complex karyotype, del(11q), SF3B1 and SAMHD1 mutations were associated with significant lower PFS. The prognostic influence varied based on the patient's IGHV status, as these abnormalities did not affect outcomes in the UM‐IGHV subgroup. TP53 mutations had no significant impact on outcomes in the M‐IGHV subgroup. Our findings highlight the diverse prognostic influence of genetic aberrations depending on the IGHV status in symptomatic CLL patients receiving first‐line CIT. The prognosis of gene mutations and cytogenetic abnormalities needs to be investigated with a compartmentalized methodology, taking into account the IGVH status of patients receiving first‐line BTK and/or BCL2 inhibitors. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. The PI3Kδ inhibitor zandelisib on intermittent dosing in relapsed/refractory follicular lymphoma: Results from a global phase 2 study.

Author

Zelenetz, Andrew D., Jurczak, Wojciech, Ribrag, Vincent, Linton, Kim, Collins, Graham P., Jiménez, Javier L., Bishton, Mark, Dholaria, Bhagirathbhai, Mengarelli, Andrea, Phillips, Tycel J., Sungala, Nagendraprasad, Musuraca, Gerardo, Sheehy, Oonagh, Van Den Neste, Eric, Odera, Mitsuhiko, Miao, Lu, Gold, Daniel P., Ghalie, Richard G., and Zinzani, Pier L.

Published
2024
Full Text
View/download PDF

10. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial

Author

Kalakonda, Nagesh, Maerevoet, Marie, Cavallo, Federica, Follows, George, Goy, Andre, Vermaat, Joost S P, Casasnovas, Olivier, Hamad, Nada, Zijlstra, Josée M, Bakhshi, Sameer, Bouabdallah, Reda, Choquet, Sylvain, Gurion, Ronit, Hill, Brian, Jaeger, Ulrich, Sancho, Juan Manuel, Schuster, Michael, Thieblemont, Catherine, De la Cruz, Fátima, Egyed, Miklos, Mishra, Sourav, Offner, Fritz, Vassilakopoulos, Theodoros P, Warzocha, Krzysztof, McCarthy, Daniel, Ma, Xiwen, Corona, Kelly, Saint-Martin, Jean-Richard, Chang, Hua, Landesman, Yosef, Joshi, Anita, Wang, Hongwei, Shah, Jatin, Shacham, Sharon, Kauffman, Michael, Van Den Neste, Eric, and Canales, Miguel A

Published
2020
Full Text
View/download PDF

12. Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study

Author

Maerevoet, Marie, Zijlstra, Josee M., Follows, George, Casasnovas, Rene-Olivier, Vermaat, J. S. P., Kalakonda, Nagesh, Goy, Andre, Choquet, Sylvain, Van Den Neste, Eric, Hill, Brian, Thieblemont, Catherine, Cavallo, Federica, De la Cruz, Fatima, Kuruvilla, John, Hamad, Nada, Jaeger, Ulrich, Caimi, Paolo, Gurion, Ronit, Warzocha, Krzysztof, Bakhshi, Sameer, Sancho, Juan-Manuel, Schuster, Michael, Egyed, Miklos, Offner, Fritz, Vassilakopoulos, Theodoros P., Samal, Priyanka, Ku, Matthew, Ma, Xiwen, Corona, Kelly, Chamoun, Kamal, Shah, Jatin, Shacham, Sharon, Kauffman, Michael G., and Canales, Miguel

Published
2021
Full Text
View/download PDF

14. A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy

Author

Bachy, Emmanuel, Maurer, Matthew J., Habermann, Thomas M., Gelas-Dore, Bénédicte, Maucort-Boulch, Delphine, Estell, Jane A., Van den Neste, Eric, Bouabdallah, Réda, Gyan, Emmanuel, Feldman, Andrew L., Bargay, Joan, Delmer, Alain, Slager, Susan L., Gomes da Silva, Maria, Fitoussi, Olivier, Belada, David, Maisonneuve, Hervé, Intragumtornchai, Tanin, Ansell, Stephen M., Lamy, Thierry, Dartigues, Peggy, Link, Brian K., Seymour, John F., Cerhan, James R., and Salles, Gilles

Published
2018
Full Text
View/download PDF

15. Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study

Author

Dartigeas, Caroline, Van Den Neste, Eric, Léger, Julie, Maisonneuve, Hervé, Berthou, Christian, Dilhuydy, Marie-Sarah, De Guibert, Sophie, Leprêtre, Stéphane, Béné, Marie C, Nguyen-Khac, Florence, Letestu, Rémi, Cymbalista, Florence, Rodon, Philippe, Aurran-Schleinitz, Thérèse, Vilque, Jean-Pierre, Tournilhac, Olivier, Mahé, Béatrice, Laribi, Kamel, Michallet, Anne-Sophie, Delmer, Alain, Feugier, Pierre, Lévy, Vincent, Delépine, Roselyne, Colombat, Philippe, and Leblond, Véronique

Published
2018
Full Text
View/download PDF

17. Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study

Author

Houot, Roch, Cartron, Guillaume, Bijou, Fontanet, de Guibert, Sophie, Salles, Gilles A., Fruchart, Christophe, Bouabdallah, Krimo, Maerevoet, Marie, Feugier, Pierre, Le Gouill, Steven, Tilly, Hervé, Casasnovas, Rene-Olivier, Moluçon-Chabrot, Cécile, Van Den Neste, Eric, Zachee, Pierre, Andre, Marc, Bonnet, Christophe, Haioun, Corinne, Van Hoof, Achiel, Van Eygen, Koen, Molina, Lysiane, Nicolas-Virelizier, Emmanuelle, Ruminy, Philippe, and Morschhauser, Franck

Published
2019
Full Text
View/download PDF

19. Long-Term Follow-Up of Rituximab Maintenance in Young Patients With Mantle-Cell Lymphoma Included in the LYMA Trial: A LYSA Study.

Author

Sarkozy, Clémentine, Thieblemont, Catherine, Oberic, Lucie, Moreau, Anne, Bouabdallah, Krimo, Damaj, Gandhi, Gastinne, Thomas, Tessoulin, Benoit, Ribrag, Vincent, Casasnovas, Olivier, Haioun, Corinne, Houot, Roch, Jardin, Fabrice, Van Den Neste, Eric, Cheminant, Morgane, Morschhauser, Franck, Callanan, Mary, Safar, Violaine, Gressin, Remy, and Hermine, Olivier

Published
2024
Full Text
View/download PDF

20. R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma (HOVON/SAKK): final results of a multicentre, phase 3, open-label, randomised trial

Author

MS Hematologie, Cancer, Infection & Immunity, Regenerative Medicine and Stem Cells, Chamuleau, Martine E D, Stenner, Frank, Chitu, Dana A, Novak, Urban, Minnema, Monique C, Geerts, Paul, Stevens, Wendy B C, Zenz, Thorsten, van Imhoff, Gustaaf W, Wu, Ka Lung, Demandt, Astrid M P, Kersten, Marie Jose, Terpstra, Wim E, Tick, Lidwine W, Deeren, Dries, Van Den Neste, Eric, Gregor, Michael, Veelken, Hendrik, Böhmer, Lara H, Caspar, Clemens B, Mutsaers, Pim, Refos, Jeannine M, Sewsaran, Robby, Fu, Liping, Seefat, Rianne L, Uyl-de Groot, Carin A, Dirnhofer, Stefan, Van Den Brand, Michiel, de Jong, Daphne, Nijland, Marcel, Lugtenburg, Pieternella, MS Hematologie, Cancer, Infection & Immunity, Regenerative Medicine and Stem Cells, Chamuleau, Martine E D, Stenner, Frank, Chitu, Dana A, Novak, Urban, Minnema, Monique C, Geerts, Paul, Stevens, Wendy B C, Zenz, Thorsten, van Imhoff, Gustaaf W, Wu, Ka Lung, Demandt, Astrid M P, Kersten, Marie Jose, Terpstra, Wim E, Tick, Lidwine W, Deeren, Dries, Van Den Neste, Eric, Gregor, Michael, Veelken, Hendrik, Böhmer, Lara H, Caspar, Clemens B, Mutsaers, Pim, Refos, Jeannine M, Sewsaran, Robby, Fu, Liping, Seefat, Rianne L, Uyl-de Groot, Carin A, Dirnhofer, Stefan, Van Den Brand, Michiel, de Jong, Daphne, Nijland, Marcel, and Lugtenburg, Pieternella

Published
2023

21. Targeting CD19 in diffuse large B‐cell lymphoma: An expert opinion paper

Author

Bailly, Sarah, Cartron, Guillaume, Chaganti, Sridhar, Cordoba, Raul, Corradini, Paolo, Düll, Johannes, Ferrarini, Isacco, Osborne, Wendy, Rosenwald, Andreas, Sancho, Juan-Manuel, Tilly, Hervé, Van Den Neste, Eric, Viardot, Aandreas, Visco, Carlo, Universitat Autònoma de Barcelona, UCL - SSS/DDUV/SIGN - Cell signalling, UCL - (SLuc) Centre du cancer, and UCL - (SLuc) Service d'hématologie

Subjects
Cancer Research, CD19, Oncology, non-Hodgkin lymphoma, Antigens, CD19, diffuse large B-cell lymphoma, Humans, Lymphoma, Large B-Cell, Diffuse, Hematology, General Medicine, Expert Testimony, relapsed/refractory
Abstract

Medical writing assistance was provided by Sarah Stowell of Alligent Europe (Envision Pharma Group), funded by Incyte Biosciences International Sàrl. The ubiquitous, early-stage expression, efficient internalization, limited off-target effects, and high disease specificity of CD19 make it an attractive therapeutic target. Currently available anti-CD19 therapies have demonstrated particular promise in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Selection of the most appropriate treatment strategy should be based on individual patient characteristics and the goal of therapy. However, evidence and knowledge about the sequencing of anti-CD19 therapies are limited. Here, we review the current evidence for CD19 as a target in diffuse large B-cell lymphoma and consider approaches to the use of anti-CD19 therapy.

Published
2022
Full Text
View/download PDF

22. R-CODOX-M/R-IVA Versus DA-EPOCH-R in Patients with Newly Diagnosed Burkitt Lymphoma. Final Results of A Multicenter Randomized HOVON/SAKK Trial

Author

Chamuleau, Martine, primary, Stenner, Frank, additional, Chitu, Dana, additional, Novak, Urban, additional, Minnema, Monique, additional, Geerts, Paul, additional, Stevens, Wendy, additional, Zenz, Thorsten, additional, van Imhoff, Gustaaf, additional, Wu, Ka Lung, additional, Demandt, Astrid, additional, Kersten, Marie Jose, additional, Terpstra, Wim, additional, Tick, Lidwine, additional, Deeren, Dries, additional, Van Den Neste, Eric, additional, Gregor, Michael, additional, Veelken, Joan Hendrik, additional, Bohmer, Lara, additional, Clemens, Caspar, additional, Mutsaers, Pim G. N. J., additional, Refos, Jeannine, additional, Sewsaran, Robby, additional, Fu, Liping, additional, Seefat, Rianne, additional, Uyl-de Groot, Carin, additional, Dirnhofer, Prof. Dr. Stefan, additional, Van Den Brand, Michiel, additional, de Jong, Daphne, additional, Nijland, Marcel, additional, and Lugtenburg, Pieternella, additional

Published
2023
Full Text
View/download PDF

23. Innovations 2022 en hématologie

Author

Bailly, Sarah, Van Den Neste, Eric, Constantinescu, Stefan N., UCL - SSS/DDUV/SIGN - Cell signalling, UCL - (SLuc) Service d'hématologie, and UCL - SSS/DDUV/BCHM - Biochimie-Recherche métabolique

Subjects
Lymphome B diffus à grandes cellules en rechute ou réfractaire, Thérapies anti-CD19, Anti-CD19 therapies, Relapsing or refactory diffuse large B-cell lymphoma
Abstract

Les caractéristiques propres du marqueur cellulaire CD19 en font une cible thérapeutique idéale dans le traitement des lymphomes B. Plusieurs molécules ciblant le CD19 sont disponibles depuis peu, ou en cours de développement, et montrent des résultats prometteurs dans cette indication. Cela semble particulièrement vrai dans la prise en charge des lymphomes B diffus à grandes cellules en rechute ou réfractaires comme le démontrent les résultats des différentes études disponibles décrites dans cet article. Le choix de la bonne molécule et de la meilleure séquence pour ces traitements reste encore à définir.

Published
2023

24. Upfront Consolidation Combining Yttrium-90 Ibritumomab Tiuxetan and High-Dose Therapy with Stem Cell Transplantation in Poor-Risk Patients with Diffuse Large B Cell Lymphoma

Author

Fruchart, Christophe, Tilly, Hervé, Morschhauser, Franck, Ghesquières, Hervé, Bouteloup, Marie, Fermé, Christophe, Van Den Neste, Eric, Bordessoule, Dominique, Bouabdallah, Reda, Delmer, Alain, Casasnovas, René Olivier, Ysebaert, Loïc, Ciappuccini, Renaud, Briere, Josette, and Gisselbrecht, Christian

Published
2014
Full Text
View/download PDF

25. Immunosuppression Is Associated With Clinical Features and Relapse Risk of B Cell Posttransplant Lymphoproliferative Disorder: A Retrospective Analysis Based on the Prospective, International, Multicenter PTLD-1 Trials

Author

Zimmermann, Heiner, Babel, Nina, Dierickx, Daan, Morschhauser, Franck, Mollee, Peter, Zaucha, Jan M., Dreyling, Martin H., Dührsen, Ulrich, Reinke, Petra, Verhoef, Gregor, Subklewe, Marion, Hüttmann, Andreas, Tousseyn, Thomas, Bachy, Emmanuel, Hauser, Ingeborg A., Tarella, Corrado, Van Den Neste, Eric, Gheysens, Olivier, Anagnostopoulos, Ioannis, Leblond, Veronique, Riess, Hanno, Choquet, Sylvain, and Trappe, Ralf U.

Published
2018
Full Text
View/download PDF

26. High frequency of GATA2 mutations in patients with mild chronic neutropenia evolving to MonoMac syndrome, myelodysplasia, and acute myeloid leukemia

Author

Pasquet, Marlène, Bellanné-Chantelot, Christine, Tavitian, Suzanne, Prade, Naïs, Beaupain, Blandine, LaRochelle, Olivier, Petit, Arnaud, Rohrlich, Pierre, Ferrand, Christophe, Van Den Neste, Eric, Poirel, Hélène A., Lamy, Thierry, Ouachée-Chardin, Marie, Mansat-De Mas, Véronique, Corre, Jill, Récher, Christian, Plat, Geneviève, Bachelerie, Françoise, Donadieu, Jean, and Delabesse, Eric

Published
2013
Full Text
View/download PDF

27. Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial

Author

Wulf, Gerald G, Altmann, Bettina, Ziepert, Marita, D'Amore, Francesco, Held, Gerhard, Greil, Richard, Tournilhac, Olivier, Relander, Thomas, Viardot, Andreas, Wilhelm, Martin, Wilhelm, Christian, Pezzutto, Antonio, Zijlstra, Josee M, Van Den Neste, Eric, Lugtenburg, Pieternella J, Doorduijn, Jeanette K, Gelder, Michel van, van Imhoff, Gustaaf W, Zettl, Florian, Braulke, Friederike, Nickelsen, Maike, Glass, Bertram, Rosenwald, Andreas, Gaulard, Philippe, Loeffler, Markus, Pfreundschuh, Michael, Schmitz, Norbert, Trümper, Lorenz, ACT-2 study investigators, UCL - SSS/DDUV - Institut de Duve, UCL - SSS/DDUV/BCHM - Biochimie-Recherche métabolique, UCL - (SLuc) Service d'hématologie, UCL - (SLuc) Centre du cancer, Hematology, CCA - Cancer Treatment and quality of life, Role of intra-Clonal Heterogeneity and Leukemic environment in ThErapy Resistance of chronic leukemias (CHELTER), Université Clermont Auvergne (UCA), RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, and MUMC+: MA Hematologie (9)

Subjects
0301 basic medicine, Male, cd52 expression, Cancer Research, epstein-barr-virus, medicine.medical_treatment, CHOP, Gastroenterology, PROPHYLAXIS, 0302 clinical medicine, Cause of Death, Antineoplastic Combined Chemotherapy Protocols, Medicine, Significant risk, Alemtuzumab, ComputingMilieux_MISCELLANEOUS, Aged, 80 and over, Hematology, lymphoproliferative disorders, Hazard ratio, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, Middle Aged, CHEMOTHERAPY, Prognosis, 3. Good health, Treatment Outcome, Oncology, Vincristine, 030220 oncology & carcinogenesis, Toxicity, PHASE-II, Female, medicine.drug, medicine.medical_specialty, prognostic-factors, Medication Adherence, 03 medical and health sciences, SDG 3 - Good Health and Well-being, Internal medicine, Humans, non-hodgkin-lymphoma, Cyclophosphamide, Aged, Chemotherapy, therapy, business.industry, Lymphoma, T-Cell, Peripheral, DETUDE-DES-LYMPHOMES, medicine.disease, Survival Analysis, Peripheral T-cell lymphoma, 030104 developmental biology, Doxorubicin, Prednisone, business
Abstract

PTCL patients exhibit poor survival with existing treatments. We investigated the efficacy of CHOP combined with alemtuzumab in 116 PTCL patients age 61–80 in an open-label, randomized phase 3 trial. Alemtuzumab was given on day 1, to a total of 360 mg in 21 patients, or 120 mg in 37. Hematotoxicity was increased with A-CHOP resulting in more grade ≥3 infections (40% versus 21%) and 4 versus 1 death due to infections, respectively. CR/CRu rate was 60% for A-CHOP and 43% for CHOP, and OR rate was 72% and 66%, respectively. Three-year-EFS, PFS and OS were 27% [15%–39%], 28% [15%–40%], and 37% ([23%–50%] for A-CHOP, and 24% [12%–35%], 29% [17%–41%], and 56% [44%–69%] for CHOP, respectively, showing no significant differences. Multivariate analyses, adjusted for strata and sex confirmed these results (hazard ratio HREFS: 0.7 ([95% CI: 0.5–1.1]; p = 0.094), HRPFS: 0.8 ([95% CI: 0.5–1.2]; p = 0.271), HROS: 1.4 ([95% CI: 0.9–2.4]; p = 0.154). The IPI score was validated, and male sex (HREFS 2.5) and bulky disease (HREFS 2.2) were significant risk factors for EFS, PFS, and OS. Alemtuzumab added to CHOP increased response rates, but did not improve survival due to treatment-related toxicity.

Published
2021
Full Text
View/download PDF

28. Cellular response to COVID-19 vaccines in hematologic malignancies patients: a new hope for non-responders?

Author

UCL - SSS/DDUV - Institut de Duve, UCL - SSS/DDUV/BCHM - Biochimie-Recherche métabolique, UCL - SSS/DDUV/SIGN - Cell signalling, UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - SSS/IREC/MBLG - Pôle de Microbiologie médicale, UCL - (SLuc) Service de médecine interne générale, UCL - (SLuc) Service de biochimie médicale, UCL - (SLuc) Service de microbiologie, UCL - (SLuc) Service d'hématologie, Saad Albichr, Imane, De Greef, Julien, Van Den Neste, Eric, Poire, Xavier, Havelange, Violaine, Vekemans, Marie-Christiane, Bailly, Sarah, Yombi, Jean Cyr, Mzougui, Samy, Scohy, Anaïs, Kabamba-Mukadi, Benoît, UCL - SSS/DDUV - Institut de Duve, UCL - SSS/DDUV/BCHM - Biochimie-Recherche métabolique, UCL - SSS/DDUV/SIGN - Cell signalling, UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - SSS/IREC/MBLG - Pôle de Microbiologie médicale, UCL - (SLuc) Service de médecine interne générale, UCL - (SLuc) Service de biochimie médicale, UCL - (SLuc) Service de microbiologie, UCL - (SLuc) Service d'hématologie, Saad Albichr, Imane, De Greef, Julien, Van Den Neste, Eric, Poire, Xavier, Havelange, Violaine, Vekemans, Marie-Christiane, Bailly, Sarah, Yombi, Jean Cyr, Mzougui, Samy, Scohy, Anaïs, and Kabamba-Mukadi, Benoît

Abstract

SARS-CoV-2 vaccines offered great hope in controlling the worldwide COVID-19 pandemic. At present, SARS-CoV-2 vaccines have shown excellent efficacy to prevent COVID-19 but immunocompromised patients were left-off most vaccine clinical trials albeit their extreme vulnerability. Indeed, immunosuppression is associated with a higher risk of developing severe COVID-19 with mortality rates over 30% reported in patients with hematologic malignancies (HM). [...]

Published
2022

29. Ibrutinib Associated with Rituximab-Platinum Salt-Based Immunochemotherapy in B-Cell Lymphomas: Results of a Phase 1b-II Study of the LYSA Group.

Author

UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Bonnet, Christophe, Dupuis, Jehan, Tilly, Hervé, Lamy, Thierry, Fruchart, Christophe, le Gouill, Steven, Thieblemont, Catherine, Morschhauser, Franck, Casasnovas, Olivier, Bouabdallah, Krimo, Ghesquieres, Hervé, Van Den Neste, Eric, André, Marc, Cartron, Guillaume, Salles, Gilles, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Bonnet, Christophe, Dupuis, Jehan, Tilly, Hervé, Lamy, Thierry, Fruchart, Christophe, le Gouill, Steven, Thieblemont, Catherine, Morschhauser, Franck, Casasnovas, Olivier, Bouabdallah, Krimo, Ghesquieres, Hervé, Van Den Neste, Eric, André, Marc, Cartron, Guillaume, and Salles, Gilles

Abstract

In the post-rituximab era, patients with relapsed/refractory non-Hodgkin B-cell lymphoma (R/R B-NHL) responding to a platinum salt-based salvage regimen can potentially be cured after intensification followed by autologous stem cell transplantation, with the quality of the response to salvage predicting survival. The Bruton tyrosine kinase inhibitor ibrutinib, given as monotherapy or combined with other molecules, has proven effective in numerous B-cell lymphomas. To evaluate the safety of the combination of ibrutinib, rituximab, dexamethasone, and cytarabine with either cisplatin (R-DHAP) or oxaliplatin (R-DHAOx), we conducted a multicenter Phase 1b-II study in transplant-eligible R/R B-NHL patients, with ibrutinib given using a 3-by-3 dose-escalation design. The combination of R-DHAP and ibrutinib (given from Day 1 to Day 21 of each cycle) was associated with dose-limiting hematological, infectious, and renal toxicities, while we were unable to reach a dose to recommend for Phase II. R-DHAOx could only be combined with a daily dosage of 280 mg ibrutinib when administered continuously. R-DHAP combined with intermittent ibrutinib administration (from Day 5 to Day 18) was found to be highly toxic. On the other hand, when this administration schedule was combined with R-DHAOx, ibrutinib dosing could be increased up to 560 mg but with relevant toxicities. Despite a strong rationale for combining ibrutinib and R-DHAP/R-DHAOx, as both target lymphoma B-cells by different mechanisms, this approach was limited by significant toxicities.

Published
2022

30. Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA study.

Author

UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Centre du cancer, UCL - (SLuc) Service de gastro-entérologie, UCL - (SLuc) Unité d'oncologie médicale, Bachy, Emmanuel, Houot, Roch, Feugier, Pierre, Bouabdallah, Krimo, Bouabdallah, Reda, Virelizier, Emmanuelle Nicolas, Maerevoet, Marie, Fruchart, Christophe, Snauwaert, Sylvia, Le Gouill, Steven, Marolleau, Jean-Pierre, Molina, Lysiane, Moluçon-Chabrot, Cécile, Thieblemont, Catherine, Tilly, Hervé, Bijou, Fontanet, Haioun, Corinne, Van den Neste, Eric, Fabiani, Bettina, Meignan, Michel, Cartron, Guillaume, Salles, Gilles, Casasnovas, Olivier, Morschhauser, Franck, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Centre du cancer, UCL - (SLuc) Service de gastro-entérologie, UCL - (SLuc) Unité d'oncologie médicale, Bachy, Emmanuel, Houot, Roch, Feugier, Pierre, Bouabdallah, Krimo, Bouabdallah, Reda, Virelizier, Emmanuelle Nicolas, Maerevoet, Marie, Fruchart, Christophe, Snauwaert, Sylvia, Le Gouill, Steven, Marolleau, Jean-Pierre, Molina, Lysiane, Moluçon-Chabrot, Cécile, Thieblemont, Catherine, Tilly, Hervé, Bijou, Fontanet, Haioun, Corinne, Van den Neste, Eric, Fabiani, Bettina, Meignan, Michel, Cartron, Guillaume, Salles, Gilles, Casasnovas, Olivier, and Morschhauser, Franck

Abstract

Obinutuzumab and lenalidomide (referred to as the GALEN combination) is an active immunomodulatory combination with a manageable safety profile in multiple types of lymphoma. We report efficacy and safety results for the phase 2 GALEN study in previously untreated patients with advanced follicular lymphoma (FL). Eligible patients aged ≥18 years had an Eastern Cooperative Oncology Group performance status ≤2 and high-tumor burden, grade 1 to 3a FL. Induction treatment was obinutuzumab (1000 mg IV, days 8, 15, and 22, cycle 1; day 1, cycles 2-6) plus lenalidomide (20 mg/d, days 1-21, cycle 1; days 2-22, cycles 2-6) for six 28-day cycles. Maintenance included obinutuzumab (1000 mg every 2 cycles) plus lenalidomide (10 mg, days 2-22) for ≤12 cycles (year 1) followed by obinutuzumab (1000 mg every 56 days) for 6 cycles (year 2). The primary end point was complete response rate (CRR) after induction per the 1999 International Working Group criteria. From October 2015 to February 2017, a total of 100 patients were enrolled. CRR after induction was 47%, and the overall response rate (ORR) was 92%. Post hoc analyses per the 2014 Lugano classification, including patients with missing bone marrow assessments, identified an additional 13 patients fulfilling CRR criteria, resulting in a complete metabolic response of 80% and an ORR of 94%. At a median follow-up of 3.7 years, 3-year progression-free survival and overall survival were 82% and 94%, respectively. The most common adverse event was neutropenia (48% any grade; 47% grade ≥3). Only 2% of patients presented with febrile neutropenia; others were mainly grade ≤2. No other specific grade ≥3 toxicity occurred at a frequency >3%. Overall, these results showed promising clinical efficacy for the chemotherapy-free GALEN backbone in previously untreated patients with high tumor burden FL. Except for neutropenia, the safety profile of the combination is remarkable. The study was registered at clinicaltrials.gov as #NCT01582776.

Published
2022

31. Adult haemophagocytic lymphohistiocytosis: a Review.

Author

UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - SSS/DDUV/BCHM - Biochimie-Recherche métabolique, UCL - SSS/DDUV/SIGN - Cell signalling, UCL - SSS/IREC/IMAG - Pôle d'imagerie médicale, UCL - (SLuc) Service de radiologie, UCL - (SLuc) Service de biologie hématologique, UCL - (SLuc) Service d'hématologie, UCL - (SLuc) Service de médecine interne générale, UCL - (SLuc) Centre de prise en charge (H.I.V.), UCL - (SLuc) Centre du cancer, Yildiz, Halil, Van Den Neste, Eric, Defour, Jean-Philippe, Danse, Etienne, Yombi, Jean Cyr, UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - SSS/DDUV/BCHM - Biochimie-Recherche métabolique, UCL - SSS/DDUV/SIGN - Cell signalling, UCL - SSS/IREC/IMAG - Pôle d'imagerie médicale, UCL - (SLuc) Service de radiologie, UCL - (SLuc) Service de biologie hématologique, UCL - (SLuc) Service d'hématologie, UCL - (SLuc) Service de médecine interne générale, UCL - (SLuc) Centre de prise en charge (H.I.V.), UCL - (SLuc) Centre du cancer, Yildiz, Halil, Van Den Neste, Eric, Defour, Jean-Philippe, Danse, Etienne, and Yombi, Jean Cyr

Abstract

BACKGROUND: Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening disorder characterized by hyperimmune response. The mortality is high despite progress being made in the diagnosis and treatment of the disease. AIM: This review aimed to update knowledge on adult HLH pathophysiology, identifiy the numerous causes, and help clinicians make early diagnosis and initiate treatment. DESIGN AND METHODS: Using Embase, we searched relevant articles published from January 1, 2010 to October 31, 2019, with the MESH term « hemophagocytic lymphohistiocytosis; macrophagic activation syndrome, adult ». RESULTS: The mean age at presentation is about 50 years, with a male predominance. The most frequent disease associations are haematological diseases, viral or bacterial infections, and autoimmune diseases. The pathophysiologic mechanism is probably the combination of inherited genetic mutations and extrinsic triggers. The mortality rate is 26.5% to 74.8%. H-score is more efficient than HLH-2004 criteria to identify HLH, with diagnostic sensitivity and specificity 90% and 79%, respectively.18F-FDG PET/CT is potentially useful for detecting underlying disease and the extent of secondary HLH. Disease-specific treatment should be given as soon as possible. Treatment with corticosteroids combined or not with etoposide is the mainstay of treatment. Monoclonal antibodies and JAK pathway inhibitors show promise of being effective. CONCLUSION: In adult HLH, infectious diseases, autoimmune disease and malignancy should be suspected so that disease-specific treatment can be given promptly. Treatment with corticosteroids combined or not with etoposide is the mainstay of treatment, but new therapies show promise of being effective.

Published
2022

32. Targeting CD19 in diffuse large B-cell lymphoma: An expert opinion paper.

Author

UCL - SSS/DDUV/SIGN - Cell signalling, UCL - (SLuc) Centre du cancer, UCL - (SLuc) Service d'hématologie, Bailly, Sarah, Cartron, Guillaume, Chaganti, Sridhar, Córdoba, Raul, Corradini, Paolo, Düll, Johannes, Ferrarini, Isacco, Osborne, Wendy, Rosenwald, Andreas, Sancho, Juan-Manuel, Tilly, Hervé, Van Den Neste, Eric, Viardot, Andreas, Visco, Carlo, UCL - SSS/DDUV/SIGN - Cell signalling, UCL - (SLuc) Centre du cancer, UCL - (SLuc) Service d'hématologie, Bailly, Sarah, Cartron, Guillaume, Chaganti, Sridhar, Córdoba, Raul, Corradini, Paolo, Düll, Johannes, Ferrarini, Isacco, Osborne, Wendy, Rosenwald, Andreas, Sancho, Juan-Manuel, Tilly, Hervé, Van Den Neste, Eric, Viardot, Andreas, and Visco, Carlo

Abstract

The ubiquitous, early-stage expression, efficient internalization, limited off-target effects, and high disease specificity of CD19 make it an attractive therapeutic target. Currently available anti-CD19 therapies have demonstrated particular promise in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Selection of the most appropriate treatment strategy should be based on individual patient characteristics and the goal of therapy. However, evidence and knowledge about the sequencing of anti-CD19 therapies are limited. Here, we review the current evidence for CD19 as a target in diffuse large B-cell lymphoma and consider approaches to the use of anti-CD19 therapy.

Published
2022

33. Innovations 2021 en hématologie

Author

UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Service d'hématologie, UCL - SSS/DDUV/MEXP - Médecine expérimentale, UCL - SSS/DDUV/BCHM - Biochimie-Recherche métabolique, UCL - SSS/DDUV/SIGN - Cell signalling, UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - (SLuc) Centre de malformations vasculaires congénitales, Vekemans, Marie-Christiane, Havelange, Violaine, Van Den Neste, Eric, Bailly, Sarah, Lambert, Catherine, Straetmans, Nicole, Poire, Xavier, Constantinescu, Stefan N., Hermans, Cédric, UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Service d'hématologie, UCL - SSS/DDUV/MEXP - Médecine expérimentale, UCL - SSS/DDUV/BCHM - Biochimie-Recherche métabolique, UCL - SSS/DDUV/SIGN - Cell signalling, UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - (SLuc) Centre de malformations vasculaires congénitales, Vekemans, Marie-Christiane, Havelange, Violaine, Van Den Neste, Eric, Bailly, Sarah, Lambert, Catherine, Straetmans, Nicole, Poire, Xavier, Constantinescu, Stefan N., and Hermans, Cédric

Published
2022

34. Bilan d'adénopathie en médecine générale : quand rassurer et quand référer ?

Author

UCL - (SLuc) Service d'hématologie, UCL - SSS/DDUV/SIGN - Cell signalling, UCL - SSS/DDUV/BCHM - Biochimie-Recherche métabolique, UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - (SLuc) Centre de malformations vasculaires congénitales, UCL - SSS/IREC/SLUC - Pôle St.-Luc, Dufour, Inès, Verstraete, Géraldine, Raedemaeker, Juliette, Andreozzi, Fabio, Bailly, Sarah, Van Den Neste, Eric, Hermans, Cédric, Vekemans, Marie-Christiane, UCL - (SLuc) Service d'hématologie, UCL - SSS/DDUV/SIGN - Cell signalling, UCL - SSS/DDUV/BCHM - Biochimie-Recherche métabolique, UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - (SLuc) Centre de malformations vasculaires congénitales, UCL - SSS/IREC/SLUC - Pôle St.-Luc, Dufour, Inès, Verstraete, Géraldine, Raedemaeker, Juliette, Andreozzi, Fabio, Bailly, Sarah, Van Den Neste, Eric, Hermans, Cédric, and Vekemans, Marie-Christiane

Published
2022

35. Cognitive compensatory processes of older, clinically fit patients with hematologic malignancies undergoing chemotherapy: A longitudinal cohort study

Author

Libert, Yves, Borghgraef, Cindy, Beguin, Yves, Delvaux, Nicole, Devos, Martine, Doyen, Chantal, Dubruille, Stéphanie, Etienne, Anne‐Marie, Liénard, Aurore, Merckaert, Isabelle, Reynaert, Christine, Slachmuylder, Jean‐Louis, Straetmans, Nicole, Van Den Neste, Eric, Bron, Dominique, and Razavi, Darius

Published
2017
Full Text
View/download PDF

36. Transformed Waldenström macroglobulinaemia: clinical presentation and outcome. A multi‐institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (FILO)

Author

Durot, Eric, Tomowiak, Cécile, Michallet, Anne‐Sophie, Dupuis, Jehan, Hivert, Bénédicte, Leprêtre, Stéphane, Toussaint, Elise, Godet, Sophie, Merabet, Fatiha, Van Den Neste, Eric, Ivanoff, Sarah, Roussel, Xavier, Zini, Jean‐Marc, Regny, Caroline, Lemal, Richard, Sutton, Laurent, Perrot, Aurore, Le Dû, Katell, Kanagaratnam, Lukshe, Morel, Pierre, Leblond, Véronique, and Delmer, Alain

Published
2017
Full Text
View/download PDF

37. Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma

Author

Le Gouill, Steven, Thieblemont, Catherine, Oberic, Lucie, Moreau, Anne, Bouabdallah, Krimo, Dartigeas, Caroline, Damaj, Gandhi, Gastinne, Thomas, Ribrag, Vincent, Feugier, Pierre, Casasnovas, Olivier, Zerazhi, Hacène, Haioun, Corinne, Maisonneuve, Hervé, Houot, Roch, Jardin, Fabrice, Van Den Neste, Eric, Tournilhac, Olivier, Le Dû, Katell, Morschhauser, Franck, Cartron, Guillaume, Fornecker, Luc-Matthieu, Canioni, Danielle, Callanan, Mary, Béné, Marie C., Salles, Gilles, Tilly, Hervé, Lamy, Thierry, Gressin, Remy, and Hermine, Olivier

Published
2017
Full Text
View/download PDF

40. Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial

Author

Lepretre, Stephane, Aurran, Therese, Mahé, Beatrice, Cazin, Bruno, Tournilhac, Olivier, Maisonneuve, Herve, Casasnovas, Olivier, Delmer, Alain, Leblond, Veronique, Royer, Bruno, Corront, Bernadette, Chevret, Sylvie, Delépine, Roselyne, Vaudaux, Sandrine, Van Den Neste, Eric, Béné, Marie Christine, Letestu, Remi, Cymbalista, Florence, and Feugier, Pierre

Published
2012
Full Text
View/download PDF

41. Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes

Author

Casasnovas, Rene-Olivier Follows, George Zijlstra, Josee M. and Vermaat, Joost S. P. Kalakonda, Nagesh Choquet, Sylvain Van den Neste, Eric Hill, Brian Thieblemont, Catherine Cavallo, Federica De la Cruz, Fatima Kuruvilla, John Hamad, Nada and Jaeger, Ulrich Caimi, Paolo F. Gurion, Ronit Warzocha, Krzysztof Bakhshi, Sameer Sancho, Juan-Manuel Schuster, Michael Egyed, Miklos Offner, Fritz Vassilakopoulos, Theodoros P. Samal, Priyanka Ku, Matthew Ma, Xiwen and Chamoun, Kamal Shah, Jatin Canales, Miguel Maerevoet, Marie and Shacham, Sharon Kauffman, Michael G. Goy, Andre

Subjects
immune system diseases, hemic and lymphatic diseases
Abstract

The phase 2b, open-label, multicenter SADAL study evaluated single agent oral selinexor, a selective inhibitor of nuclear export (SINE) compound, in patients with diffuse large B cell lymphoma (DLBCL) after >= 2 lines of systemic therapy. Similar activity was observed in GCB- and non-GCB DLBCL with a trend to higher response rates in DLBCL transformed from follicular lymphoma. Lower response rates were observed in double expressor DLBCL; higher response rates were observed in patients with baseline hemoglobin >= 10 g/dL and normal levels of C-MYC or BCL-2 expression (51%). Overall, strong single agent activity with selinexor were observed in patients with relapsed/refractory DLBCL. Background: The SADAL study evaluated oral selinexor in patients with relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL) after at least 2 prior lines of systemic therapy. In this post-hoc analysis, we analyzed the outcomes of the SADAL study by DLBCL subtype to determine the effects of DLBCL subtypes on efficacy and tolerability of selinexor. Patients and Methods: Data from 134 patients in SADAL were analyzed by DLBCL subtypes for overall response rate (ORR), overall survival (OS), duration of treatment response, progression-free survival, and adverse events rate. Results: ORR in the entire cohort was 29.1%, and similar in patients with germinal center (GCB) versus non-GCB DLBCL (31.7% vs. 24.2%, P = 0.45); transformed DLBCL showed a trend towards higher ORR than de novo DLBCL: 38.7% vs. 26.2% (P = 0.23). Despite similar prior treatment regimens and baseline characteristics, patients with DLBCL and normal C-MYC/BCL-2 protein expression levels had a significantly higher ORR (46.2% vs.14.8%, P = 0.012) and significantly longer OS (medians 13.7 vs. 5.1 months, hazard ratio 0.43 [95% CI, 0.23-0.77], P = 0.004) as compared with those whose DLBCL had C-MYC and BCL-2 overexpression. Among patients who had normal expression levels of either C-MYC or BCL-2 and baseline hemoglobin levels >= 10g/dL, ORR was 51.5% (n = 47), with median OS of 15.5 months and median PFS of 4.6 months. Similar rates of adverse events were noted in all subgroups. Conclusions: Overall, single agent oral selinexor showed strong responses in patients with limited treatment alternatives regardless of germinal center B-cell type or disease origin. (C) 2021 Elsevier Inc. All rights reserved.

Published
2022

42. Innovations 2021 en hématologie

Author

Vekemans, Marie-Christiane, Havelange, Violaine, Van Den Neste, Eric, Bailly, Sarah, Lambert, Catherine, Straetmans, Nicole, Poire, Xavier, Constantinescu, Stefan N., Hermans, Cédric, UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Service d'hématologie, UCL - SSS/DDUV/MEXP - Médecine expérimentale, UCL - SSS/DDUV/BCHM - Biochimie-Recherche métabolique, UCL - SSS/DDUV/SIGN - Cell signalling, UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, and UCL - (SLuc) Centre de malformations vasculaires congénitales

Subjects
PF4, CAR-T cells, Multiple myeloma, Antithrombin, Chronic myeloid leukemia, Myelofibrosis, PTI, Platelet factor 4
Published
2022

43. Bilan d'adénopathie en médecine générale : quand rassurer et quand référer ?

Author

Dufour, Inès, Verstraete, Géraldine, Raedemaeker, Juliette, Andreozzi, Fabio, Bailly, Sarah, Van Den Neste, Eric, Hermans, Cédric, Vekemans, Marie-Christiane, UCL - (SLuc) Service d'hématologie, UCL - SSS/DDUV/SIGN - Cell signalling, UCL - SSS/DDUV/BCHM - Biochimie-Recherche métabolique, UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, UCL - (SLuc) Centre de malformations vasculaires congénitales, and UCL - SSS/IREC/SLUC - Pôle St.-Luc

Subjects
Biopsy, Adenopathy, Malignity, General medicine
Published
2022

44. Autologous stem cell transplantation as a first-line treatment strategy for chronic lymphocytic leukemia: a multicenter, randomized, controlled trial from the SFGM-TC and GFLLC

Author

Sutton, Laurent, Chevret, Sylvie, Tournilhac, Olivier, Diviné, Marine, Leblond, Véronique, Corront, Bernadette, Leprêtre, Stéphane, Eghbali, Houchingue, Van Den Neste, Eric, Michallet, Mauricette, Maloisel, Frédéric, Bouabdallah, Krimo, Decaudin, Didier, Berthou, Christian, Brice, Pauline, Gonzalez, Hugo, Chapiro, Elise, Radford-Weiss, Isabelle, Leporrier, Nathalie, Maloum, Karim, Nguyen-Khac, Florence, Davi, Frédéric, Lejeune, Julie, Merle-Béral, Hélène, and Leporrier, Michel

Published
2011
Full Text
View/download PDF

45. Ibrutinib Associated with Rituximab-Platinum Salt-Based Immunochemotherapy in B-Cell Lymphomas: Results of a Phase 1b-II Study of the LYSA Group

Author

Bonnet, Christophe, primary, Dupuis, Jehan, additional, Tilly, Hervé, additional, Lamy, Thierry, additional, Fruchart, Christophe, additional, le Gouill, Steven, additional, Thieblemont, Catherine, additional, Morschhauser, Franck, additional, Casasnovas, Olivier, additional, Bouabdallah, Krimo, additional, Ghesquieres, Hervé, additional, Van Den Neste, Eric, additional, André, Marc, additional, Cartron, Guillaume, additional, and Salles, Gilles, additional

Published
2022
Full Text
View/download PDF

47. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

Author

Coiffier, Bertrand, Thieblemont, Catherine, Van Den Neste, Eric, Lepeu, Gérard, Plantier, Isabelle, Castaigne, Sylvie, Lefort, Sophie, Marit, Gérald, Macro, Margaret, Sebban, Catherine, Belhadj, Karim, Bordessoule, Dominique, Fermé, Christophe, and Tilly, Hervé

Published
2010
Full Text
View/download PDF

48. Glofitamab Monotherapy Provides Durable Responses after Fixed-Length Dosing in Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) Patients (pts)

Author

Dickinson, Michael, primary, Carlo-Stella, Carmelo, additional, Morschhauser, Franck, additional, Patel, Krish, additional, Khan, Cyrus, additional, Bartlett, Nancy L., additional, Iacoboni, Gloria, additional, Hertzberg, Mark, additional, Leppä, Sirpa, additional, Van Den Neste, Eric, additional, Tani, Monica, additional, Cartron, Guillaume, additional, Salar, Antonio, additional, Perez-Callejo, David, additional, Lundberg, Linda, additional, Relf, James, additional, Clark, Emma, additional, Humphrey, Kathryn, additional, and Hutchings, Martin, additional

Published
2021
Full Text
View/download PDF

49. Cellular response to COVID-19 vaccines in hematologic malignancies patients: a new hope for non-responders?

Author

Saad Albichr, Imane, primary, De Greef, Julien, additional, Van Den Neste, Eric, additional, Poiré, Xavier, additional, Havelange, Violaine, additional, Vekemans, Marie-Christiane, additional, Bailly, Sarah, additional, Yombi, Jean-Cyr, additional, Mzougui, Samy, additional, Scohy, Anaïs, additional, and Kabamba-Mukadi, Benoît, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results